Efficacy and safety of simvastatin in chronic plaque psoriasis
Keywords:
Psoriasis, simvastatin, efficacy, safetyAbstract
Objective To determine the efficacy and safety of simvastatin in chronic plaque psoriasis. Patients and methods Sixty patients of either sex, aged between 18 and 70 years were included in the study. Efficacy was determined by percentage reduction in psoriasis area and severity index (PASI) score from baseline. Safety of simvastatin was evaluated by measuring serum alanine aminotransferase (ALT), creatinine phosphokinase (CPK) and bilirubin at baseline, 4th, 8th and 12th week. The data were analyzed for variables like age, sex and percentage reduction in PASI score. Results There was >50% reduction in PASI score in 20% patients. Out of these, 8 patients had moderate plaque psoriasis and 4 patients had severe psoriasis. In remaining 80% cases simvastatin did not prove to be efficacious. The drug was safe and well-tolerated. Conclusion Simvastatin can be affective in patients with moderate disease as compared to cases with severe plaque psoriasis. The drug was safe and well-tolerated.References
Griffith C, Camp RDR, Barker JNWN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffith C. editors. Rook’s Textbook of Dermatology. Oxford: Blackwell Science; 2004. P.35.1-7.
Iyer O, Woods P. Psoriasis: a link with hyperlipidaemia; an observation in general practice. [cited 2008 December 8]. Available from: URL: http://priory.com/fam/psoriasis.html.
Ghoreshi K, Weigret C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007;25:574-80.
Lebwhol M, Tyring SK, Hamilton TK et al. A novel targeted T cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13.
Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune diseases: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358-70.
Gefland JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
Javidi Z, Meibodi NT, Nahidi Y. Serum lipid abnormalities and psoriasis. Indian J Dermatol. 2007;52:89-92.
Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol. 2007;57:529-31.
McCarey DW, Mclnnes IB, Madhok R et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo controlled trial. Lancet. 2004;363:2015-21.
Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a randomized double blind placebo controlled study. Nigerian J Med. 2010;19:1.
Gottlieb ABCC, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5-21.
